A Phase 2 Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax (rHuIL-12) in Healthy Subjects

Trial Profile

A Phase 2 Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax (rHuIL-12) in Healthy Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs NMIL 12 1 (Primary)
  • Indications Acute radiation syndrome
  • Focus Adverse reactions
  • Sponsors Neumedicines
  • Most Recent Events

    • 02 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Sep 2015 Planned End Date changed from 1 May 2015 to 1 Aug 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top